摘要
目的探讨瑞格列奈与二甲双胍联合用于2型糖尿病临床治疗中的价值。方法选取2019年12月—2020年12月该院接受治疗的120例2型糖尿病患者作为研究对象,以随机数表分组,对照组60例(二甲双胍治疗)、观察组60例(二甲双胍联合瑞格列奈治疗),比较分析两组患者的临床治疗总有效率、糖代谢指标、胰岛素指标、氧化应激指标,最后统计两组的不良反应情况。结果观察组患者的临床治疗总有效率为88.33%,与对照组的70.00%比较,差异有统计学意义(P<0.05)。治疗后,观察组患者的糖代谢指标、胰岛素指标、氧化应激指标明显优于对照组,差异有统计学意义(P<0.05)。观察组不良反应发生率为10.00%,与对照组的16.67%较接近,差异无统计学意义(P>0.05)。结论针对2型糖尿病患者临床联合给予二甲双胍与瑞格列奈,不仅可以更好地调控患者的糖代谢、胰岛素以及氧化应激指标,优化治疗效果,同时不会增加安全隐患,有利于患者预后发展。
Objective To explore the value of repaglinide combined with metformin in the clinical treatment of type 2 diabetes.Methods A total of 120 patients with type 2 diabetes who were treated in this hospital from December 2019 to December 2020 were selected as the research objects.Grouped by a random number table,60 cases in the control group(treated with metformin)and 60 cases in the observation group(treated with metformin combined with repaglinide).The total effective rate,glucose metabolism index,insulin index,oxidative stress index of the two groups of patients were compared and analyzed.Finally,the adverse reactions of the two groups were counted.Results The total effective rate of clinical treatment in the observation group was 88.33%,compared with 70.00%in the control group,the difference was statistically significant(P<0.05).After treatment,the glucose metabolism indexes,insulin indexes,and oxidative stress indexes of the observation group were significantly better than those of the control group,and the difference was statistically significant(P<0.05).The incidence of adverse reactions in the observation group was 10.00%,which was close to 16.67%in the control group,and the difference was not statistically significant(P>0.05).Conclusion The clinical combined administration of metformin and repaglinide for patients with type 2 diabetes can not only better regulate the patients'glucose metabolism,insulin and oxidative stress indicators,but also optimize the treatment effect.At the same time,it will not increase safety hazards,which is conducive to the development of the patient's prognosis.
作者
荆树贞
JING Shuzhen(Department of Internal Medicine,Shengli Shengdong Hospital,Dongying,Shandong Province,257055 China)
出处
《糖尿病新世界》
2021年第24期87-89,93,共4页
Diabetes New World Magazine
